SPRO - Spero Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.52
-0.32 (-4.68%)
As of 3:34PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close6.84
Open6.83
Bid6.52 x 800
Ask6.64 x 800
Day's Range6.52 - 6.89
52 Week Range6.45 - 19.00
Volume18,497
Avg. Volume85,547
Market Cap112.183M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.30
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.25
Trade prices are not sourced from all markets
  • GlobeNewswire16 days ago

    New Research: Key Drivers of Growth for Mersana Therapeutics, Maiden, Payment Data, CareDx, Natera, and Spero Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss
    Zackslast month

    Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss

    Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 6.25% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswirelast month

    Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview

    Pipeline rapidly advancing with three clinical trials planned to initiate by early 2019, including a SPR994 Phase 3 initiation around year-end 2018 CAMBRIDGE, Mass., Nov. 08,.

  • GlobeNewswirelast month

    Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial

    Spero Therapeutics, Inc. (SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections, today announced results from preclinical IND-enabling studies of SPR720, an oral antimicrobial agent being developed for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections. SPR720 was assessed in a series of non-clinical studies, including IND-enabling 28- and 31-day GLP toxicology studies in non-human primates and rats, respectively, and safety pharmacology studies.

  • Expedia acquires Pillow and ApartmentJet to conquer the short-term rental market
    TechCrunch2 months ago

    Expedia acquires Pillow and ApartmentJet to conquer the short-term rental market

    To keep up with the rising demand for short-term rentals in U.S. cities and compete with the home-sharing giant Airbnb, travel booking site Expedia has picked up a pair of venture-backed hospitality startups, Pillow and ApartmentJet. Employees of both companies will join Expedia . "Acquiring Pillow and ApartmentJet will help unlock urban growth opportunities that, over time, will contribute to HomeAway's ability to add an even broader selection of accommodations to its marketplace and marketplaces across Expedia Group brands, ensuring travelers always find the perfect place to stay," the company explained in a statement.

  • Expedia Group (EXPE) Q3 Earnings Beat, Revenues Surge Y/Y
    Zacks2 months ago

    Expedia Group (EXPE) Q3 Earnings Beat, Revenues Surge Y/Y

    Expedia Group (EXPE) continues to benefit from the robust performance of HomeAway, Brand Expedia, Expedia Partner Solutions and Hotels.com in third-quarter 2018.

  • Reuters2 months ago

    UPDATE 2-Expedia beats profit estimates on HomeAway, travel bookings growth

    Expedia Group Inc saw major growth in its vacation rental business HomeAway and higher travel bookings in the third quarter, helping it to beat Wall Street's profit estimates on Thursday. Expedia said customers spent 24 percent more on HomeAway bookings and that the business, which competes with Airbnb, is headed for strong revenue and profit growth this year. Amobi, however, warned that the fourth quarter may not be as strong as the third and a key thing to watch would be whether Expedia is able to maintain this type of growth trajectory.

  • Expedia Inc Del (EXPE) Q3 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Expedia Inc Del (EXPE) Q3 2018 Earnings Conference Call Transcript

    EXPE earnings call for the period ending September 30, 2018.

  • Expedia Earnings Beat Estimates, Fueled by Home-Rentals Growth
    Bloomberg2 months ago

    Expedia Earnings Beat Estimates, Fueled by Home-Rentals Growth

    Analysts had predicted $3.10 a share, according to data compiled by Bloomberg. Expedia, which owns travel aggregator websites like Hotels.com, Hotwire.com and CarRentals.com, is starting to see the benefits of buying HomeAway three years ago. Expedia paid $3.9 billion in 2015 for the vacation-home rental site in a power play to rival upstart Airbnb Inc. Along with Booking Holdings Inc., the three have been battling to woo travelers and go beyond typical vacation packages to expand offerings in people’s homes in cities.

  • War against the superbugs: Mass. biotechs step up to fight antibiotic resistance
    American City Business Journals2 months ago

    War against the superbugs: Mass. biotechs step up to fight antibiotic resistance

    In a world where superbugs are overpowering various antibiotic drugs, threatening millions of lives, Massachusetts biotechs are fighting hard to ensure the bugs don't become the industry's kryptonite.

  • What's in the Cards for Expedia Group (EXPE) in Q3 Earnings?
    Zacks2 months ago

    What's in the Cards for Expedia Group (EXPE) in Q3 Earnings?

    Expedia Group (EXPE) Q3 results to benefit from well-performing segments that are likely to boost gross bookings.

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero Therapeutics, Aimmune Therapeutics, and Cars — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
    Zacks2 months ago

    The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena

    The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena

  • GlobeNewswire2 months ago

    Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR206

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced today that SPR206, a product candidate within Spero’s Potentiator Platform, has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for the treatment of complicated urinary tract infections (cUTI) and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). “We are pleased that the FDA recognized the potential of SPR206’s novel approach to treat multidrug-resistant Gram-negative infections and provided it with QIDP status,” said Ankit Mahadevia, M.D., CEO of Spero Therapeutics.

  • Benzinga3 months ago

    The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sep. 27) Edwards Lifesciences Corp (NYSE: EW ) Applied Genetic ...

  • GlobeNewswire3 months ago

    Spero Announces Positive SPR994 Phase 1 SAD/MAD Final Results

    Spero Therapeutics, Inc. (SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company focused on developing and commercializing novel antibiotics to treat multi-drug resistant bacterial infections, today reported positive results from a final analysis of its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of SPR994, its investigational oral carbapenem product candidate designed for the treatment of Gram-negative infections. The study was conducted in healthy volunteers to assess the safety, tolerability and pharmacokinetics of SPR994.  Dose escalation within the MAD portion of the Phase 1 clinical trial demonstrated that 600 mg of SPR994 provides greater drug exposure than was observed in the first dosing cohort of 300 mg while maintaining a favorable safety profile.

  • GlobeNewswire3 months ago

    Spero Therapeutics Announces Presentations at IDWeek 2018

    CAMBRIDGE, Mass., Sept. 25, 2018 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • GlobeNewswire3 months ago

    Spero Therapeutics to Present at the Cantor Global Healthcare Conference in October

    Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections. Spero is advancing SPR994, a carbapenem-class antibiotic, which is designed to be the first broad-spectrum oral antibiotic for use in adults to treat MDR Gram-negative infections. The product candidates are two IV-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting.

  • Who Owns Most Of Spero Therapeutics Inc (NASDAQ:SPRO)?
    Simply Wall St.3 months ago

    Who Owns Most Of Spero Therapeutics Inc (NASDAQ:SPRO)?

    Every investor in Spero Therapeutics Inc (NASDAQ:SPRO) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning sharesRead More...

  • How to Set Up a Smart Lock for Your Airbnb or Rental Property
    Consumer Reports3 months ago

    How to Set Up a Smart Lock for Your Airbnb or Rental Property

    Consumer Reports has no financial relationship with advertisers on this site. Internet-connected smart locks replace or augment your property’s existing deadbolt and give you the ability to create access codes (for use with a keypad that’s connected to the lock) and electronic keys (where a smartphone app acts as the key).